EGFR and non-small cell lung carcinoma: Between November 2014 and December 2021, a total of 140 patients pathologically confirmed to have NSCLC harbouring EGFR driving mutations were included in the study, among which 68 (49%) patients had wild‐type TS, and the remaining 72 (51%) patients were confirmed to have different TS polymorphism variations.